MX2020007130A - Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. - Google Patents
Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.Info
- Publication number
- MX2020007130A MX2020007130A MX2020007130A MX2020007130A MX2020007130A MX 2020007130 A MX2020007130 A MX 2020007130A MX 2020007130 A MX2020007130 A MX 2020007130A MX 2020007130 A MX2020007130 A MX 2020007130A MX 2020007130 A MX2020007130 A MX 2020007130A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- metastatic cancers
- axl
- treating metastatic
- decoy receptors
- Prior art date
Links
- 208000037819 metastatic cancer Diseases 0.000 title abstract 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 108700015048 receptor decoy activity proteins Proteins 0.000 title 1
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 abstract 2
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 abstract 1
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004952 protein activity Effects 0.000 abstract 1
- 238000011287 therapeutic dose Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Marine Sciences & Fisheries (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581671P | 2017-11-04 | 2017-11-04 | |
| US201862618916P | 2018-01-18 | 2018-01-18 | |
| US201862681944P | 2018-06-07 | 2018-06-07 | |
| PCT/US2018/059218 WO2019090227A1 (en) | 2017-11-04 | 2018-11-05 | Methods of treating metastatic cancers using axl decoy receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007130A true MX2020007130A (es) | 2021-02-15 |
Family
ID=66333375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007130A MX2020007130A (es) | 2017-11-04 | 2018-11-05 | Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200289613A1 (https=) |
| EP (1) | EP3703731A4 (https=) |
| JP (1) | JP7286179B2 (https=) |
| KR (1) | KR20200085307A (https=) |
| CN (1) | CN111565742B (https=) |
| AU (2) | AU2018359863A1 (https=) |
| CA (1) | CA3080732A1 (https=) |
| MX (1) | MX2020007130A (https=) |
| WO (1) | WO2019090227A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4062914A4 (en) | 2019-11-18 | 2024-01-17 | Inxmed (Nanjing) Co., Ltd. | USE OF AN FAK INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF TUMORS PRESENTING AN NRAS MUTATION |
| WO2021141892A1 (en) * | 2020-01-06 | 2021-07-15 | Aravive Inc. | Methods of treating clear cell renal carcinoma (ccrcc) using axl decoy receptors |
| EP4101453A4 (en) | 2020-02-05 | 2024-05-15 | Inxmed (Nanjing) Co., Ltd. | COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS |
| GB202004189D0 (en) * | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| MX2023000810A (es) * | 2020-07-19 | 2023-05-19 | Aravive Inc | Metodos de diagnostico para el cancer utilizando receptores señuelo axl. |
| TW202313044A (zh) * | 2021-08-16 | 2023-04-01 | 大陸商應世生物科技（南京）有限公司 | Ｉｎ１００１８與ｐｌｄ的聯用 |
| EP4398937A4 (en) * | 2021-09-11 | 2025-07-09 | Aravive Inc | METHODS FOR TREATING LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA USING AXL DECOY RECEPTORS AS FIRST-LINE THERAPY |
| CN120418281A (zh) * | 2022-12-29 | 2025-08-01 | 财团法人生物技术开发中心 | 靶向PD-L1和中和Gas6之融合蛋白及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
| DK2352763T4 (da) | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
| PL2387395T3 (pl) * | 2009-01-16 | 2015-03-31 | Rigel Pharmaceuticals Inc | Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym |
| PT2525824T (pt) | 2010-01-22 | 2017-07-13 | Univ Leland Stanford Junior | Inibição da sinalização de axl em terapêutica antimetastática |
| US9074192B2 (en) * | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA2894539C (en) * | 2012-12-14 | 2021-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US10876176B2 (en) * | 2014-12-18 | 2020-12-29 | Aravive Biologics, Inc. | Antifibrotic activity of GAS6 inhibitor |
| JP7042739B2 (ja) * | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| US20180140679A1 (en) | 2016-11-23 | 2018-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of axl receptor activity in combination with cytoreductive therapy |
-
2018
- 2018-11-05 EP EP18872866.1A patent/EP3703731A4/en active Pending
- 2018-11-05 CA CA3080732A patent/CA3080732A1/en active Pending
- 2018-11-05 MX MX2020007130A patent/MX2020007130A/es unknown
- 2018-11-05 AU AU2018359863A patent/AU2018359863A1/en not_active Abandoned
- 2018-11-05 KR KR1020207016082A patent/KR20200085307A/ko not_active Ceased
- 2018-11-05 WO PCT/US2018/059218 patent/WO2019090227A1/en not_active Ceased
- 2018-11-05 JP JP2020523776A patent/JP7286179B2/ja active Active
- 2018-11-05 CN CN201880084046.2A patent/CN111565742B/zh active Active
- 2018-11-05 US US16/761,246 patent/US20200289613A1/en not_active Abandoned
-
2023
- 2023-08-01 US US18/228,879 patent/US20240009271A1/en not_active Abandoned
-
2025
- 2025-03-06 AU AU2025201654A patent/AU2025201654A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111565742A (zh) | 2020-08-21 |
| EP3703731A1 (en) | 2020-09-09 |
| RU2020116224A3 (https=) | 2022-05-06 |
| WO2019090227A1 (en) | 2019-05-09 |
| JP2021502334A (ja) | 2021-01-28 |
| KR20200085307A (ko) | 2020-07-14 |
| JP7286179B2 (ja) | 2023-06-05 |
| US20200289613A1 (en) | 2020-09-17 |
| CA3080732A1 (en) | 2019-05-09 |
| EP3703731A4 (en) | 2021-07-21 |
| AU2018359863A1 (en) | 2020-07-02 |
| RU2020116224A (ru) | 2021-12-06 |
| AU2025201654A1 (en) | 2025-03-27 |
| US20240009271A1 (en) | 2024-01-11 |
| CN111565742B (zh) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020007130A (es) | Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. | |
| MX2017007321A (es) | Terapias de combinacion. | |
| PH12016501171A1 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| MX2019001517A (es) | Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer. | |
| MX2023012451A (es) | Composiciones para usarse en el tratamiento de una enfermedad autoinmune y cancer. | |
| WO2011091305A3 (en) | Inhibition of axl signaling in anti-metastatic therapy | |
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| MX382472B (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinación con radioterapia. | |
| Froeling et al. | Homeostatic restoration of desmoplastic stroma rather than its ablation slows pancreatic cancer progression | |
| MX2019008158A (es) | Terapia de combinacion para el tratamiento del cancer. | |
| MX2009007597A (es) | Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer. | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| WO2016100738A3 (en) | Antifibrotic activity of gas6 inhibitor | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| PH12018500254A1 (en) | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof | |
| MX380835B (es) | Terapia de combinación pac-1. | |
| MX2020004960A (es) | Asociacion de activos para tratar el cancer de prostata. | |
| PH12015502266A1 (en) | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| EP4706653A3 (en) | Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers | |
| MX2021004603A (es) | Dosificacion. |